Redx Pharma in discussions over possible bid

Writer,

Drug discovery and development firm Redx Pharma said it is in discussions over a possible cash offer from an investor group led by biotech industry figure Sam Waksal.

The company said the announcement did not amount to a firm intention to make an offer and there can be no certainty that any offer will be made, with Waksal having until 5pm on 28 January 2020 to make a firm bid or walk away.

The company is trying several avenues to secure funding to take its lead cancer drug to the next stage of clinical trials.

The company is asking shareholders for permission to swap a £2.5mln loan from its largest shareholder, Moulton Goodies, for shares at a price of 5.25p per share.

At 8:29am: (LON:REDX) Redx Pharma Plc share price was +2.13p at 8.75p


Related content

Redx Pharma gets 15p/share takeover approach from Yesod Bio-Sciences

Cancer and fibrosis focused Redx Pharma said it had received a takeover approach from Yesod Bio-Sciences.

The approach may lead to a cash offer of...

Fri, 13/03/2020 - 07:28


Redx Pharma posts annual loss as it develops drug candidates

Pharmaceutical group Redx Pharma posted a full-year loss as it continued to develop its oncology and fibrosis treatment candidates.

Pre-tax losses for the year through...

Wed, 11/03/2020 - 08:11


Redx Pharma agrees to £26.3m funding injection from Redmile, Sofinnova

Cancer and fibrosis focused Redx Pharma said healthcare investor Redmile had agreed to provide, together with Sofinnova Partners, it with up to £26.3m of funding....

Mon, 02/03/2020 - 09:16


Redx Pharma awarded UK grant funding for biomarker development

Redx Pharma said that it and partner Medicines Discovery Catapult had been awarded UK government grant funding to cover the development of a panel of...

Tue, 19/11/2019 - 09:24


Redx Pharma to present poster for lung disease treatment at Madrid conference

Redx Pharma said a poster related to its treatment for the rare lung disease idiopathic pulmonary fibrosis would be presented at a key conference in...

Mon, 23/09/2019 - 09:44